NCT02009761View on ClinicalTrials.gov

Multiple Rising Does Study (Subcutaneous Doses) of BI 655064 in Male and Female Patients With Chronic Primary Immune Thrombocytopenic Purpura (ITP).

PHASE1TerminatedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

December 18, 2013

Primary Completion Date

April 26, 2016

Study Completion Date

April 26, 2016

Conditions
Purpura, Thrombocytopenic, Idiopathic
Interventions
DRUG

BI 655064

subcutaneous injection

Trial Locations (2)

10021

New York Hospital, Cornell Medical Center, New York

90033

University of Southern California, Los Angeles

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY

NCT02009761 - Multiple Rising Does Study (Subcutaneous Doses) of BI 655064 in Male and Female Patients With Chronic Primary Immune Thrombocytopenic Purpura (ITP). | Biotech Hunter | Biotech Hunter